Ultragenyx Pharmaceutical (RARE)
NASDAQ:RARE
Want to see RARE full AI Analyst Report?
RARE Stock Chart & Stats
$24.81
-$0.60(-1.35%)
At close: 4:00 PM EST
$24.81
-$0.60(-1.35%)
Day’s Range― - ―
52-Week Range$18.29 - $42.37
Previous CloseN/A
Volume75.38K
Average Volume (3M)2.01M
Market Cap
$2.46B
Enterprise Value$3.49B
Total Cash (Recent Filing)$413.00M
Total Debt (Recent Filing)$1.20B
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Jul 30, 2026EPS Estimate
-1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.11
Shares Outstanding98,489,230
10 Day Avg. Volume1,673,765
30 Day Avg. Volume2,011,664
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)-28.35
Price to Sales (P/S)3.37
P/FCF Ratio-4.80
Enterprise Value/Market Cap1.42
Enterprise Value/Revenue5.21
Enterprise Value/Gross Profit6.23
Enterprise Value/Ebitda-6.78
Forecast
1Y Price Target
$48.86Price Target Upside96.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-4.49
Revenue Forecast (FY)$741.94M
Bulls Say, Bears Say
Bulls Say
Cost Reduction And Path To ProfitabilityStrategic restructuring, including workforce reductions and lower research spending, is expected to meaningfully reduce operating costs and support a clear path toward profitability as commercial revenues grow.
Late-stage Clinical ReadoutsA positive ASPIRE Phase 3 readout for GTX-102 in Angelman syndrome could materially increase valuation by validating the company's late-stage gene therapy franchise.
Regulatory Progress And Commercial ReadinessFDA acceptance of DTX401 for priority review combined with planned U.S. manufacturing at the new gene therapy facility supports a faster path to commercialization and revenue realization if approval is granted.
Bears Say
Regulatory Uncertainty And ResubmissionsIncomplete responses to resubmitted biologics applications and requests for additional manufacturing documentation create regulatory uncertainty and could delay approval timelines and commercialization.
Revenue And Valuation DownsideAnalyst reductions in price targets and sales forecasts after clinical setbacks and softer product guidance indicate downside pressure from lower-than-expected revenue and revised valuation assumptions.
Safety Profile ConcernsMild-to-moderate liver reactions and an isolated treatment-related acute hepatitis episode raise uncertainty about the gene therapies' risk-benefit profile and may prompt closer regulatory scrutiny or label restrictions.
Ultragenyx Pharmaceutical News
RARE FAQ
What was Ultragenyx Pharmaceutical’s price range in the past 12 months?
Ultragenyx Pharmaceutical lowest stock price was $18.29 and its highest was $42.37 in the past 12 months.
What is Ultragenyx Pharmaceutical’s market cap?
Ultragenyx Pharmaceutical’s market cap is $2.46B.
When is Ultragenyx Pharmaceutical’s upcoming earnings report date?
Ultragenyx Pharmaceutical’s upcoming earnings report date is Jul 30, 2026 which is in 75 days.
How were Ultragenyx Pharmaceutical’s earnings last quarter?
Ultragenyx Pharmaceutical released its earnings results on May 05, 2026. The company reported -$1.84 earnings per share for the quarter, missing the consensus estimate of -$1.488 by -$0.352.
Is Ultragenyx Pharmaceutical overvalued?
According to Wall Street analysts Ultragenyx Pharmaceutical’s price is currently Undervalued.
Does Ultragenyx Pharmaceutical pay dividends?
Ultragenyx Pharmaceutical does not currently pay dividends.
What is Ultragenyx Pharmaceutical’s EPS estimate?
Ultragenyx Pharmaceutical’s EPS estimate is -1.23.
How many shares outstanding does Ultragenyx Pharmaceutical have?
Ultragenyx Pharmaceutical has 98,489,230 shares outstanding.
What happened to Ultragenyx Pharmaceutical’s price movement after its last earnings report?
Ultragenyx Pharmaceutical reported an EPS of -$1.84 in its last earnings report, missing expectations of -$1.488. Following the earnings report the stock price went up 3.679%.
Which hedge fund is a major shareholder of Ultragenyx Pharmaceutical?
Currently, no hedge funds are holding shares in RARE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ultragenyx Pharmaceutical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.86 (96.93% Upside)
$48.86 (96.93% Upside)
Blogger Sentiment
Bullish
RARE Sentiment 67%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $691.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.48%
12-Months-Change
Fundamentals
Return on Equity
1566.94%
Trailing 12-Months
Asset Growth
-1.21%
Trailing 12-Months
Company Description
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
RARE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balances strong commercial execution, clear revenue guidance (reaffirmed $730M–$760M for 2026), rapid pipeline progress (two near-term PDUFAs and promising long-term GTX-102 data with Bayley-4 and MDRI signals), and manufacturing/launch readiness against meaningful near-term financial pressure (Q1 net loss of $185M, $197M cash used in operations, high operating expenses and restructuring charges). Management presented a credible path to profitability in 2027 with planned R&D/SG&A reductions and assumed PRV monetization, but timing uncertainty for Phase 3 readouts, quarter-to-quarter ordering variability and execution risks around launches and PRV realization remain. Overall the positives around product performance, global commercialization scale, and upcoming catalysts outweigh the near-term financial and execution risks.View all RARE earnings summariesRARE Stock 12 Month Forecast
Average Price Target
$48.86
▲(96.93% Upside)
Technical Analysis
Travere Therapeutics
―
Xenon
―
Disc Medicine
―
Tarsus Pharmaceuticals
―
Mineralys Therapeutics, Inc.
―
Ownership Overview
3.93% Insiders
20.80% Mutual Funds
13.00% Other Institutional Investors
46.35% Public Companies and Individual Investors